Michael J. Morris, MD, on Prostate Cancer: Impact of PSMA-Targeted Imaging on Clinical Management
ASCO20 Virtual Scientific ProgramMichael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III data from the CONDOR trial, which showed that PSMA-targeted PET scans detected and localized occult disease in most men with biochemically recurrent prostate cancer presenting with negative or equivocal conventional imaging findings (Abstract 5501).
Related Videos
Christopher Sweeney, MBBS, and Thomas Powles, MD, PhD, on Urothelial Cancer: The JAVELIN Bladder 100 Study on Avelumab vs Best Supportive Care
Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, talks with Thomas Powles, MD, PhD, of Queen Mary University of London, about the first study to d...
Seema A. Khan, MD, MPH, on Metastatic Breast Cancer: Systemic vs Locoregional Therapies
Seema A. Khan, MD, MPH, of the Lynn Sage Comprehensive Breast Center, discusses phase III trial results showing that in newly diagnosed metastatic stage IV breast cancer, loc...
Welcome to This Year’s Meeting: A Message From ASCO President Howard A. Burris III, MD, FACP, FASCO
Howard A. Burris III, MD, FACP, FASCO, President of ASCO, talks about what to expect from this year’s ASCO20 Virtual Scientific Program and its many offerings.
David C. Fajgenbaum, MD, MBA, on Chasing His Cure: A Physician Is Battling His Disease and Beating the Odds
David C. Fajgenbaum, MD, MBA, of the University of Pennsylvania, who trained as an oncologist, summarizes his opening lecture, a dramatic story of his battle against Castlema...
Howard A. Burris III, MD, FACP, FASCO, on Highlights of the ASCO20 Virtual Scientific Program
Howard A. Burris III, MD, FACP, FASCO, talks about some of the reports of research developments he is looking forward to and how future conferences could incorporate virtual ...
